Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 685
  • Print this page
  • Email this page

    Article Cited by others

REVIEW ARTICLE

Favipiravir and its potentials in COVID-19 pandemic: An update

Tam Dao Ngoc Hien, Qarawi Ahmad T, Luu Mai Ngoc, Turnage Morgan, Tran Linh, Tawfik Gehad Mohamed, Minh Le Huu Nhat, Huy Nguyen Tien, Iiyama Tatsuo, Kita Kyoshi, Hirayama Kenji

Year : 2021| Volume: 14| Issue : 10 | Page no: 433-439

   This article has been cited by
 
1 Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2
Jordi Doijen, Koen Temmerman, Christel Van den Eynde, Annick Diels, Nick Van den Broeck, Michiel Van Gool, Inha Heo, Steffen Jaensch, Marleen Zwaagstra, Mayra Diosa Toro, Winston Chiu, Steven De Jonghe, Pieter Leyssen, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Lore Verschueren, Christophe Buyck, Frank Van Kuppeveld, Johan Neyts, Marnix Van Loock, Ellen Van Damme
Microorganisms. 2023; 11(3): 717
[Pubmed]  [Google Scholar] [DOI]
2 Effects of Vitamin C on the Oral-Nasal Mucosal Damage Caused by Favipiravir in Old and Young Rats
Yücel Kurt, Özlem Özmen
Cureus. 2022;
[Pubmed]  [Google Scholar] [DOI]
3 Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats
A. Lektemur Alpan, G. Torumtay Cin, Ö. Özmen, M. F. Dogan, Y. Sahin
Journal of Evolutionary Biochemistry and Physiology. 2022; 58(2): 430
[Pubmed]  [Google Scholar] [DOI]
4 STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, V. V. Eremeev, L. F. Sabirov, E. V. Semeleva
Pharmacy & Pharmacology. 2021; 9(6): 454
[Pubmed]  [Google Scholar] [DOI]

 

Read this article